Quick Answer
Eloxx Pharmaceuticals, Inc. reported R&D Expense of $14.59 million for fiscal year 2020.
Eloxx Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2020 | $14.59M | -44.6% |
| 2019 | $26.35M | +28.6% |
| 2018 | $20.49M | +24.9% |
| 2017 | $16.40M | +2135.1% |
| 2017 | $733.7K | -91.8% |
| 2016 | $8.99M | +311.6% |
| 2016 | $2.18M | -62.6% |
| 2015 | $5.84M | +27.9% |
| 2015 | $4.57M | +36.8% |
| 2014 | $3.34M | +60.0% |
| 2013 | $2.09M | -18.7% |
| 2012 | $2.57M | -31.0% |
| 2011 | $3.72M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2021 | $4.07M | -14.6% | +26.1% |
| September 30, 2020 | $3.23M | -52.5% | -8.4% |
| June 30, 2020 | $3.53M | -51.9% | -26.0% |
| March 31, 2020 | $4.77M | -20.8% | -29.9% |
| September 30, 2019 | $6.80M | +25.6% | -7.3% |
| June 30, 2019 | $7.34M | +76.9% | +21.9% |
| March 31, 2019 | $6.02M | +37.0% | +11.2% |
| September 30, 2018 | $5.42M | +65.1% | +30.5% |
- Eloxx Pharmaceuticals, Inc. showed a decrease of -44.6% in R&D Expense compared to the prior fiscal year.
- Over the 2011–2020 period, Eloxx Pharmaceuticals, Inc.’s r&d expense has grown by 292.2% (from $3.72 million to $14.59 million).
- The most recent figure is from Eloxx Pharmaceuticals, Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 12, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: